[go: up one dir, main page]

WO2012125832A3 - Agents antimicrobiens - Google Patents

Agents antimicrobiens Download PDF

Info

Publication number
WO2012125832A3
WO2012125832A3 PCT/US2012/029234 US2012029234W WO2012125832A3 WO 2012125832 A3 WO2012125832 A3 WO 2012125832A3 US 2012029234 W US2012029234 W US 2012029234W WO 2012125832 A3 WO2012125832 A3 WO 2012125832A3
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial agents
relates
agents
infective
proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/029234
Other languages
English (en)
Other versions
WO2012125832A2 (fr
Inventor
Erin M. Duffy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Priority to BR112013023536A priority Critical patent/BR112013023536A2/pt
Priority to CA2829993A priority patent/CA2829993A1/fr
Priority to PH1/2013/501882A priority patent/PH12013501882A1/en
Priority to EP12756938.2A priority patent/EP2686308A2/fr
Priority to SG2013068630A priority patent/SG193424A1/en
Priority to AU2012229127A priority patent/AU2012229127A1/en
Publication of WO2012125832A2 publication Critical patent/WO2012125832A2/fr
Publication of WO2012125832A3 publication Critical patent/WO2012125832A3/fr
Priority to IL228388A priority patent/IL228388A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne le domaine des agents anti-infectieux, anti‑prolifératifs, anti-inflammatoires et pro-cinétiques. L'invention concerne plus particulièrement des composés aromatiques substitués utilisés comme agents thérapeutiques.
PCT/US2012/029234 2011-03-15 2012-03-15 Agents antimicrobiens Ceased WO2012125832A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR112013023536A BR112013023536A2 (pt) 2011-03-15 2012-03-15 agentes antimicrobianos
CA2829993A CA2829993A1 (fr) 2011-03-15 2012-03-15 Agents antimicrobiens
PH1/2013/501882A PH12013501882A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
EP12756938.2A EP2686308A2 (fr) 2011-03-15 2012-03-15 Agents antimicrobiens
SG2013068630A SG193424A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
AU2012229127A AU2012229127A1 (en) 2011-03-15 2012-03-15 Antimicrobial agents
IL228388A IL228388A0 (en) 2011-03-15 2013-09-12 Antimicrobial agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452884P 2011-03-15 2011-03-15
US61/452,884 2011-03-15

Publications (2)

Publication Number Publication Date
WO2012125832A2 WO2012125832A2 (fr) 2012-09-20
WO2012125832A3 true WO2012125832A3 (fr) 2012-11-08

Family

ID=46831352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029234 Ceased WO2012125832A2 (fr) 2011-03-15 2012-03-15 Agents antimicrobiens

Country Status (8)

Country Link
EP (1) EP2686308A2 (fr)
AU (1) AU2012229127A1 (fr)
BR (1) BR112013023536A2 (fr)
CA (1) CA2829993A1 (fr)
IL (1) IL228388A0 (fr)
PH (1) PH12013501882A1 (fr)
SG (1) SG193424A1 (fr)
WO (1) WO2012125832A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737145B2 (en) 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
PH12012500734A1 (en) 2009-10-16 2012-11-26 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
BR112014009217A2 (pt) * 2011-10-17 2017-04-18 Zoetis Llc antibacterianos à base de fenicol
UA110436C2 (en) 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
BR112015006243A2 (pt) * 2012-09-26 2017-07-04 Zoetis Llc agentes antibacterianos de fenicol
CA2905340C (fr) 2013-03-12 2022-05-31 Celtaxsys, Inc. Formulations orales a faible dose d'acebilustat
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
EP2968265A4 (fr) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
MX360040B (es) * 2013-04-17 2018-10-18 Zoetis Services Llc Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
AU2014315045A1 (en) 2013-09-09 2016-03-24 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3039025A4 (fr) 2013-09-09 2017-05-31 Melinta Therapeutics, Inc. Composés antimicrobiens et procédés de fabrication et d'utilisation de ces composés
KR20180015114A (ko) 2015-03-11 2018-02-12 멜린타 테라퓨틱스, 인크. 항미생물 화합물 및 이의 제조 및 사용 방법
EP3452479A1 (fr) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobiens et leurs procédés de préparation et d'utilisation
CN106631872A (zh) * 2016-12-13 2017-05-10 浙江普洛家园药业有限公司 一种氟苯尼考类似物中间体的合成方法
WO2019232306A1 (fr) 2018-05-31 2019-12-05 Celtaxsys, Inc. Procédé de réduction d'exacerbations pulmonaires chez des patients atteints d'une maladie respiratoire
WO2020262996A1 (fr) * 2019-06-25 2020-12-30 (주)앰틱스바이오 Composé dérivé introduisant un groupe biphényle dans un nouvel acide aminoalcanoïque et composition pharmaceutique antifongique le comprenant
CN115745823B (zh) * 2022-11-03 2024-02-23 武夷学院 一种化合物的制备方法及其应用
CN115806501B (zh) * 2022-12-13 2025-01-07 中国药科大学 N-草酰-d-苯丙氨酸类化合物及其酯类前药、制法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US5567844A (en) * 1984-02-03 1996-10-22 Zambon S.P.A. Process for preparing 1-phenyl-2-amino-3-fluoro-1-propanols
US20060014743A1 (en) * 2002-03-08 2006-01-19 Schering-Plough Animal Health Corporation Methods of preventing bacterial infections with florfenicol-type antibiotics
WO2008143729A2 (fr) * 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Composés macrolides et procédés pour leur fabrication et leur utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361557A (en) * 1980-01-28 1982-11-30 Schering Corporation 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor
US5567844A (en) * 1984-02-03 1996-10-22 Zambon S.P.A. Process for preparing 1-phenyl-2-amino-3-fluoro-1-propanols
US20060014743A1 (en) * 2002-03-08 2006-01-19 Schering-Plough Animal Health Corporation Methods of preventing bacterial infections with florfenicol-type antibiotics
WO2008143729A2 (fr) * 2007-02-28 2008-11-27 Rib-X Pharmaceuticals, Inc. Composés macrolides et procédés pour leur fabrication et leur utilisation

Also Published As

Publication number Publication date
BR112013023536A2 (pt) 2016-12-06
CA2829993A1 (fr) 2012-09-20
PH12013501882A1 (en) 2013-10-14
WO2012125832A2 (fr) 2012-09-20
EP2686308A2 (fr) 2014-01-22
SG193424A1 (en) 2013-10-30
IL228388A0 (en) 2013-12-31
AU2012229127A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
WO2012125832A3 (fr) Agents antimicrobiens
ZA202002470B (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP2875029B8 (fr) Composés anti-infectieux 5,5-hétéroaromatiques
CO6811873A2 (es) Compuesto de dihidroisoxazol parasiticida
PT2693885T (pt) Efeito antimicrobiano sinérgico
ZA201305193B (en) Antimicrobial composition
PH12013501654A1 (en) Pesticidal compositions and processes related thereto
EP2723396A4 (fr) Oligomères d'alkylaminoalkyle utilisés comme agents antimicrobiens à large spectre
IL229148A0 (en) Coating preparations containing 2,2'-biphenol
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
BR112014013609A2 (pt) composição antimicrobiana sólida, método da desinfecção de uma superfície e utilização de uma composição
EP3037093A4 (fr) Composition contenant un composé monoacétyldiacylglycérol comme principe actif pour la prévention ou le traitement de maladies pulmonaires obstructives chroniques
HK1201067A1 (en) Sialic acid analogs
WO2012170720A3 (fr) Méthodes et compositions pour le traitement du cancer du cerveau
WO2012170573A3 (fr) Nouveaux stabilisateurs taccalonolides de microtubules
EP3037091A4 (fr) Composition contenant un composé de monoacétyldiacylglycérol en tant que principe actif pour prévenir ou traiter l'asthme
AP2013007143A0 (en) Antimicrobial composition
EP3064203A4 (fr) Composition pharmaceutique servant à la prévention ou au traitement de maladies hépatiques contenant comme constituant efficace un précurseur de plasmalogène, un plasmalogène ou un analogue de plasmalogène
WO2012061165A3 (fr) Procédés et compositions d'amélioration de propriétés admet
EP2866569B8 (fr) Composition antimicrobienne
WO2013009678A3 (fr) Compositions et méthodes de traitement d'infection par un norovirus
GB201117072D0 (en) Use of non e.164 msisdns
HUP1100597A2 (en) Primycin or its components or combination for the treatment or prevention of infestations by special organisms
ZA201403911B (en) Antimicrobial composition
HK1177597A (en) New synergistic compositions for the treatment of topical viral infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756938

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2829993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010462

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013558178

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012756938

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012229127

Country of ref document: AU

Date of ref document: 20120315

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201391311

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020137027125

Country of ref document: KR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013023536

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: JP

ENP Entry into the national phase

Ref document number: 112013023536

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130913